Skip to main content

Table 5 The HR of etiology in the studies

From: Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Authors (year) Study design Aetiology Endpoint HR
Kudo et al. (2011) [15] RCT trial HBV = 20% TTP 0.81(0.62–1.07)
   HCV = 60%   
Bai et al. (2013) [46] Comparative study HBV = 87.9% OS 1.01(0.60–1.71)
   HCV = 4.9%   
Muhammad et al. (2013) [47] Comparative study ST:HCV = 69% OS 1.04(0.66–1.63)
   DT:HCV = 93%   
Zhao et al. (2013) [41] Non-comparative study HBV = 80% OS 1.372(0.773–2.437)
   HCV = 5%   
Hu et al. (2014) [14] Comparative study ST:B = 82.9% TTP 1.01(0.76–1.34)
   T:B = 79.8%   
Yao et al. (2016) [12] Comparative study ST:HBV = 84% OS 1.228(0.593–2.540)
   T:HBV = 83% TTP 0.878(0.494–1.561)
  1. Abbreviations: HR hazard ratio, OS overall survival, TTP time to progression, RCT randomized controlled trials, ST sorafenib plus TACE, DT DEB –TACE